Clinical Trial

Clinical and Radiographic Evaluation of Propolis as a Hemostatic Agent in Full Pulpotomy of Mature Permanent Molars With Irreversible Pulpitis

Completed
View on ClinicalTrials.gov →
Summary
The goal of this randomized clinical trial is to assess the effectiveness of propolis as a hemostatic agent in full pulpotomy for mature permanent molars with irreversible pulpitis, compared to sodium hypochlorite (NaOCl). The study also compares how bioceramic putty performs compared to mineral trioxide aggregate (MTA) as pulpotomy dressing materials. Participants will be randomly allocated into four groups (15 patients each) according to the hemostatic agent and dressing material used: * Propolis + bioceramic putty * Propolis + MTA * Sodium hypochlorite + bioceramic putty * Sodium hypochlorite + MTA Bleeding time and postoperative pain will be recorded. Clinical and radiographic success will be evaluated at 1, 3, and 6 months following treatment.
Protocol Amendment History 4 changes
critical Trial completed 2026-08-12
critical Phase changed: Phase 2 -> not applicable 2026-08-12
notable Primary completion pushed: 2025-08 -> 2026-03-16 2026-08-12
minor Completion pushed: 2026-02 -> 2026-03-16 2026-08-12
Trial Details
NCT Number NCT06679075
Lead Sponsor Misr International University
Conditions Irreversible Pulpitis
Enrollment 60 participants
Start Date 2024-11-01
Primary Completion 2026-03-16 (estimated)
Study Completion 2026-03-16 (estimated)
Updated on ClinicalTrials.gov 2026-08-11